Cargando…
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of care in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). The availability of several EGFR tyrosine kinase inhibitors approved for use in the first-line or later settings in N...
Autores principales: | Harvey, R Donald, Adams, Val R, Beardslee, Tyler, Medina, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448811/ https://www.ncbi.nlm.nih.gov/pubmed/32567494 http://dx.doi.org/10.1177/1078155220931926 |
Ejemplares similares
-
Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023) -
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019) -
Comprehensive assessment of pretreatment sarcopenia impacts on patients with
EGFR
‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023) -
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
por: Lu, Shun, et al.
Publicado: (2021) -
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
por: Hochmair, Maximilian J., et al.
Publicado: (2018)